Definition: Vasculitis refers to inflammation of blood vessels, leading to changes such as thickening, weakening, narrowing, or scarring of the vessel walls.
Classification:
Large vessel vasculitis: Affects large arteries (e.g., giant cell arteritis, Takayasu arteritis).
Small vessel vasculitis: Affects small arteries, arterioles, capillaries, and venules (e.g., granulomatosis with polyangiitis, microscopic polyangiitis, Henoch-Schönlein purpura).
ANA and rheumatoid factor (in some types of secondary vasculitis).
Anemia of chronic disease, leukocytosis, and elevated creatinine in cases with renal involvement.
Imaging:
Angiography (CT or MRI): Useful for large and medium vessel vasculitis to detect vessel stenosis or aneurysms.
PET scan: May help in detecting active inflammation in large vessel vasculitis.
Biopsy:
Gold standard for definitive diagnosis, particularly in suspected cases of small vessel vasculitis.
Treatment
Corticosteroids:
First-line treatment for most forms of vasculitis.
High-dose steroids are used initially, followed by a tapering regimen.
Immunosuppressive Agents:
Cyclophosphamide, methotrexate, azathioprine: Often used in conjunction with corticosteroids for more severe or refractory cases.
Rituximab: Commonly used in ANCA-associated vasculitis (GPA, MPA).
Biologics:
Tocilizumab: Approved for giant cell arteritis.
IVIG: Used for Kawasaki disease.
Essential Points
Vasculitis is classified by the size of the affected vessels: large, medium, or small.
Diagnosis requires a combination of clinical suspicion, laboratory testing (e.g., ANCA), imaging, and often biopsy.
Prompt treatment with corticosteroids and immunosuppressants can prevent serious complications.
Some forms, such as giant cell arteritis and ANCA-associated vasculitis, are medical emergencies due to the risk of vision loss or organ damage.
Drug toxicity monitoring and prevention are critical to limit long-term damage from therapies, especially glucocorticoids and immunosuppressive agents.